Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A S RuppertS J Mandrekar

Abstract

Ibrutinib therapy is safe and effective in patients with chronic lymphocytic leukemia (CLL). Currently, ibrutinib is administered continuously until disease progression. Combination regimens with ibrutinib are being developed to deepen response which could allow for ibrutinib maintenance (IM) discontinuation. Among untreated older patients with CLL, clinical investigators had the following questions: (i) does ibrutinib + venetoclax + obinutuzumab (IVO) with IM have superior progression-free survival (PFS) compared with ibrutinib + obinutuzumab (IO) with IM, and (ii) does the treatment strategy of IVO + IM for patients without minimal residual disease complete response (MRD- CR) or IVO + IM discontinuation for patients with MRD- CR have superior PFS compared with IO + IM. Conventional designs randomize patients to IO with IM or IVO with IM to address the first objective, or randomize patients to each treatment strategy to address the second objective. A sequential multiple assignment randomized trial (SMART) design and analysis is proposed to address both objectives. A SMART design strategy is appropriate when comparing adaptive interventions, which are defined by an individual's sequence of treatment decisions and guided by int...Continue Reading

References

Nov 12, 2005·Clinical Trials : Journal of the Society for Clinical Trials·Philip W Lavori, Ree Dawson
Jan 5, 2006·The American Journal of Psychiatry·Thomas R Insel
Nov 1, 2007·Journal of the National Cancer Institute·Peter F ThallRandall E Millikan
Jun 24, 2008·Statistics in Medicine·Marcel Wolbers, Jeffrey D Helterbrand
Jan 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine K MatthayJudith G Villablanca
Sep 15, 2009·Statistics in Medicine·Yufan ZhaoDonglin Zeng
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Working Group
Sep 8, 2012·Journal of the American Statistical Association·Lu WangPeter F Thall
Oct 3, 2012·Psychological Methods·Inbal Nahum-ShaniSusan A Murphy
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Apr 16, 2014·Clinical Trials : Journal of the Society for Clinical Trials·Kelley M Kidwell
Apr 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fabiola Cervantes-GomezVarsha Gandhi
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
A S RuppertS J Mandrekar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Steve Nicholson
The Lancet Infectious Diseases
Justin Stebbing, Angus Dalgleish
Maryland State Medical Journal
R Breitenecker
© 2022 Meta ULC. All rights reserved